Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split
October 10, 2013 at 16:15 PM EDT
Aastrom Biosciences (Nasdaq: ASTM ), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announced today that its board of directors has approved a one-for-twenty reverse stock split of the company's common stock effective on October 16, 2013. The company has filed
